幽门螺杆菌根除与灭幽门螺杆菌煎剂对慢性胃炎病变和胃黏膜屏障的影响

Effect of Helicobacter pylori eradication therapy and H pylori-killing Decoction on chronic gastritis and gastric mucosa barrier

AIM: To investigate the effect of Helicobacterpylori(Hpylon) eradication therapy and H pylori-Killing Decoction on chronic pathological mucosal changes. METHODS: Forty-six chronic gastritis patients with positive H pylori were orally administered with Livzon Weisanlian (Bismuth agent 0.22 g, b.i.d. + Tinidazole 0.5 g, b.i.d. + Clarithromycin 0.25 g. b.i.d) for 7 days for eradication of H pylori. The patients were then randomly divided into 3 groups, treated with H pylori-Killing Decoction, Weifuchun and Gastropine respectively. After 3-month treatment, gastroscopy and histopathological biopsy of antrum and corpus were performed to assess the pathological changes of gastric mucosa. Meanwhile, the serum concentration of epidermal growth factor (EGF), the mucosal content of phospholipid and epidermal growth factor receptor (EGFR) was also detected. RESULTS: After the eradication treatment of Hpylori, the acute inflammation of gastric mucosa was reduced obviously, but no evident influence on chronic pathological changes was observed. After 3-month treatment with H pylori-Killing Decoction and Weifuchun, the chronic pathological changes of gastric mucosa were improved significantly. The mucosal content of phospholipid was increased remarkably, and the serum levels of EGF were decreased significantly in both groups. However, the mucosal EGFR expression was significantly increased in H pylori-killing decoction group, but not Weifuchun goup. CONCLUSION: H pylori-killing Decoction has therapeutic effect on the chronic pathological changes of H pylori-related gastritis and protective effect on gastric mucosa barrier.